Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02282514 · ClinicalTrials.gov registry record · Phase 1
Stem Cell Transplantation for Stiff Person Syndrome (SPS)
A Phase 1 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02282514 is a Phase 1 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 23 participants.
The verdict
NCT02282514, a Phase 1 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
Non-myeloablative regimens (as the investigators use herein) are designed to maximally suppress the immune system without destruction of the bone marrow stem cell compartment. When using a non-myeloablative regimen recovery occurs without infusion of stem cells and the stem cells are autologous. While not necessary for recovery, stem cell infusion may shorten the interval of neutropenia and attendant complications. Thus in reality there is no transplant only an autologous supportive blood product. Based on our encouraging results of non-myeloablative hematopoietic stem cell transplantation, for patients with multiple sclerosis and chronic inflammatory demyelinating polyneuropathy, the investigators will investigate the role of non-myeloablative hematopoietic stem cell transplantation for patients with SPS who require assistance to ambulate.
Interventions
- DRUG Cyclophosphamide
- DRUG Mesna
- DRUG Methylprednisolone
- DRUG rATG
- BIOLOGICAL Autologous Hematopoietic Stem Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-10 |
| Est. Completion | 2019-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02282514
The ClinicalTrials.gov registry entry for NCT02282514 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02282514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02282514 about?
NCT02282514 is a clinical study titled "Stem Cell Transplantation for Stiff Person Syndrome (SPS)". Non-myeloablative regimens (as the investigators use herein) are designed to maximally suppress the immune system without destruction of the bone marrow stem cell compartment. When using a non-myeloablative regimen recovery occurs without infusion of stem cells and the stem cells are autologous. Wh...
What is the current status of trial NCT02282514?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2014-10. Estimated completion is 2019-08-30.
What interventions are being tested in trial NCT02282514?
The interventions under investigation include: Cyclophosphamide (DRUG), Mesna (DRUG), Methylprednisolone (DRUG), rATG (DRUG), Autologous Hematopoietic Stem Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02282514?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.